Clinical Trials Browser

Phase 2 × atezolizumab × Gastrointestinal × Clear all

NCT04661150 2026-04-16

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

Phase 2 Active not recruiting

42 enrolled 9 charts

Gastrointestinal

Stomach Neoplasms

NCT05211323 2026-04-13

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Phase 2 Active not recruiting

Gastrointestinal

Liver Neoplasms

NCT07235293 2026-04-09

A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.

Phase 2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT06096779 2026-04-03

Kirros

Phase 2 Recruiting

Gastrointestinal

Digestive System Neoplasms, Fatty Liver, Fibrosis, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

NCT04820179 2026-04-02

Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05733598 2026-04-02

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Phase 2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

NCT05359861 2026-03-18

Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms

NCT05528952 2026-03-16

TERTIO

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04563338 2026-03-05

An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT04721132 2026-03-05

Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer

Phase 2 Active not recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06603818 2026-02-19

Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

Phase 2 Withdrawn

Gastrointestinal

Colorectal Neoplasms

NCT05733611 2026-02-02

RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC

Phase 2 Terminated

Gastrointestinal

Colorectal Neoplasms

NCT05009069 2026-01-22

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT03228667 2026-01-14

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Phase 2 Active not recruiting

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT05152472 2026-01-08

ATEZOGIST

Phase 2 Recruiting

GastrointestinalSarcoma

Neoplasms, Gastrointestinal Stromal Tumors

NCT05174650 2025-12-05

Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements

Phase 2 Active not recruiting

Gastrointestinal

Cholangiocarcinoma

NCT05836584 2025-12-01

Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer

Phase 2 Active not recruiting

Gastrointestinal

Clinical Stage I Gastric Cancer AJCC v8

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07239245 2025-11-25

ATTACH

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05620771 2025-10-20

Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

Phase 2 Suspended

Gastrointestinal

Carcinoma, Hepatocellular

NCT06789757 2025-10-07

(HCC)

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05377034 2025-10-06

STRATUM

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT06784947 2025-10-02

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT02982694 2025-10-01

Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer

Phase 2 Terminated

Gastrointestinal

Colorectal Neoplasms, Activated Protein C Resistance

NCT04727307 2025-09-30

AB-LATE02

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases

NCT07192185 2025-09-25

Systemic Chemotherapy With FOLFOX Plus Atezolizumab & Bevacizumab for Patients With Advanced HCC Who Previously Received Atezolizumab & Bevacizumab

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05537402 2025-09-24

LOST-B

Phase 2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

NCT04273061 2025-09-22

CAPTIV-8

Phase 2 Recruiting

BreastDermatologicGastrointestinalHead & NeckSarcomaThoracic

Breast Neoplasms, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Neoplasms, Unknown Primary, Sarcoma, Skin Neoplasms, Urogenital Neoplasms

NCT05168163 2025-09-16

Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05690048 2025-08-06

FLORA

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT03421288 2025-07-25

DANTE

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT03519295 2025-06-27

SCARCE

Phase 2 Completed

Gastrointestinal

Anus Neoplasms

NCT05118724 2025-06-15

ANTONIO

Phase 2 Active not recruiting

Gastrointestinal

Turcot syndrome, Colorectal Neoplasms

NCT03448835 2025-06-08

PANDA

Phase 2 Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT04017455 2025-06-08

TARZAN

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT05870800 2025-05-25

NICER

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT05999812 2025-05-25

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms

NCT04941287 2025-05-23

Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer

Phase 2 Active not recruiting

57 enrolled 13 charts

Gastrointestinal

Gallbladder Neoplasms, Cholangiocarcinoma

NCT06339424 2025-05-14

PhotonAB

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT05750030 2025-05-06

FMT in IT-refractory HCC - FAB-HCC Pilot Study

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT06390059 2025-04-30

EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT05448677 2025-04-20

ABE-LIVER

Phase 2 Terminated

Gastrointestinal

Carcinoma, Hepatocellular

NCT06555133 2025-04-09

METEORITE

Phase 2 Recruiting

Gastrointestinal

Colorectal Carcinoma Metastatic in the Liver

NCT05243862 2025-03-18

Safety and Activity of PolyPEPI1018 Plus Atezolizumab in Colorectal Cancer.

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Cancer Metastatic

NCT05992220 2025-02-21

ALERT-HCC

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT05776875 2025-01-15

Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC

Phase 2 Terminated

3 enrolled 6 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT05007613 2025-01-01

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Squamous Cell, Esophageal Neoplasms, Neoplasm Metastasis

NCT05456165 2024-12-31

Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

Phase 2 Withdrawn

Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT03946358 2024-12-20

VolATIL

Phase 2 Completed

GastrointestinalGynecologicHead & Neck

Anal Canal Carcinoma, Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms

NCT05625893 2024-11-29

Proton Beam Radiotherapy Followed by Tecentriq and Avastin for Primary Liver Cancer With Vp2-4 Portal Vein Invasion

Phase 2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular